

ASX ANNOUNCEMENT

Enrolment target achieved for major Alzheimer's trial - XanADu

- Significant milestone achieved for XanADu trial, with the target 174 patients enrolled
- Recruitment now closed for new patients
- Study will surpass the enrolment target as the final few patients undergo evaluation for trial eligibility
- Final XanADu patient enrolment number to be confirmed within the next few weeks, triggering countdown to study completion and announcement of results in Q2 2019

Sydney 29 October 2018. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is delighted to announce that XanADu, the Phase II clinical trial of Xanamem in the treatment of Alzheimer's disease, has achieved enrolment of the planned 174 patients.


While patient recruitment has closed, the study will surpass the planned 174 patients as the final few patients undergo evaluation for trial eligibility. The Company looks forward to confirming the final patient enrolment number over the next few weeks.

Once the last patient has been enrolled into XanADu, the countdown to study completion and announcement of the top-line results will commence.

CEO of Actinogen Medical, Dr Bill Ketelbey commented: "We are delighted to have achieved our target enrolment into XanADu ahead of schedule, and eagerly await confirmation of the last patient being enrolled within the next few weeks. Enrolment of the last patient will be particularly significant for the trial, and the Company, as it will trigger the count-down to completion of the study and announcement of the results. We look forward to updating the market on this major milestone in November".

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
 @BillKetelbey

Investor and Media Enquiries

Ben Walsh
WE Buchan
M: +61 411 520 012
E: bwalsh@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other

diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol – the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, is enrolling 174 patients at 25 research sites across Australia, the UK and the USA. Enrolment is expected to complete in Q4 2018, with top-line results expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.